(E)-tert-butyl 4-(4-cinnamamidophenyl)piperazine-1-carboxylate | 1580002-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (E)-tert-butyl 4-(4-cinnamamidophenyl)piperazine-1-carboxylate
• 英文别名: tert-butyl 4-[4-[[(E)-3-phenylprop-2-enoyl]amino]phenyl]piperazine-1-carboxylate
• CAS: 1580002-61-4
• 化学式: C₂₄H₂₉N₃O₃
• 分子量: 407.513
• InChiKey: NEWNPTGZCAHEOZ-NTEUORMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-tert-butyl 4-(4-cinnamamidophenyl)piperazine-1-carboxylate 在 三氟乙酸 、 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 12.17h， 以92.92%的产率得到(E)-N-[4-(piperazin-1-yl)phenyl]cinnamamide
  参考文献：
  名称：

  Design, synthesis and antitubercular evaluation of novel series of N-[4-(piperazin-1-yl)phenyl]cinnamamide derivatives

  摘要：

  The analogs of N-[4-(piperazin-1-yl)phenyl]cinnamamide were designed and synthesized by molecular hybridization approach in which part C of the designed molecule was linked through amide and carbamate functionality that improves the physicochemical properties and govern the pharmacokinetic and pharmacodynamic behavior. The systematic modification was done around the Part C to explore the structure activity relationship of antitubercular cinnamamide. All 52 compounds were evaluated for its antitubercular activity against Mycobacterium tuberculosis (M. tb) using Resazurin microtitre plate assay (REMA). Compound 11g with trifluoromethyl substitution exhibited good antitubercular activity of 3.125 mu g/ml. The synthesized N[4-(piperazin-1-yl)phenyl]cinnamamide derivatives showed promising activity against M. tb. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.024
• 作为产物：
  描述：

  N-Boc-哌嗪 在 吡啶 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 、 乙酸乙酯 为溶剂， 90.0 ℃ 、689.49 kPa 条件下， 反应 21.0h， 生成 (E)-tert-butyl 4-(4-cinnamamidophenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Design, synthesis and antitubercular evaluation of novel series of N-[4-(piperazin-1-yl)phenyl]cinnamamide derivatives

  摘要：

  The analogs of N-[4-(piperazin-1-yl)phenyl]cinnamamide were designed and synthesized by molecular hybridization approach in which part C of the designed molecule was linked through amide and carbamate functionality that improves the physicochemical properties and govern the pharmacokinetic and pharmacodynamic behavior. The systematic modification was done around the Part C to explore the structure activity relationship of antitubercular cinnamamide. All 52 compounds were evaluated for its antitubercular activity against Mycobacterium tuberculosis (M. tb) using Resazurin microtitre plate assay (REMA). Compound 11g with trifluoromethyl substitution exhibited good antitubercular activity of 3.125 mu g/ml. The synthesized N[4-(piperazin-1-yl)phenyl]cinnamamide derivatives showed promising activity against M. tb. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.024

文献信息

• Design, synthesis and antitubercular evaluation of novel series of N-[4-(piperazin-1-yl)phenyl]cinnamamide derivatives
  作者：Kavitkumar N. Patel、Vikas N. Telvekar

  DOI：10.1016/j.ejmech.2014.01.024

  日期：2014.3

  The analogs of N-[4-(piperazin-1-yl)phenyl]cinnamamide were designed and synthesized by molecular hybridization approach in which part C of the designed molecule was linked through amide and carbamate functionality that improves the physicochemical properties and govern the pharmacokinetic and pharmacodynamic behavior. The systematic modification was done around the Part C to explore the structure activity relationship of antitubercular cinnamamide. All 52 compounds were evaluated for its antitubercular activity against Mycobacterium tuberculosis (M. tb) using Resazurin microtitre plate assay (REMA). Compound 11g with trifluoromethyl substitution exhibited good antitubercular activity of 3.125 mu g/ml. The synthesized N[4-(piperazin-1-yl)phenyl]cinnamamide derivatives showed promising activity against M. tb. (C) 2014 Elsevier Masson SAS. All rights reserved.